Teva Agilect Labeling Not Yet Negotiated With FDA; User Fee Date Is Aug. 4
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Agilect (rasagiline) has not yet been negotiated with FDA despite the Parkinson's disease agent's August 4 user fee date, Teva says